Harpreet S. Bajaj
A5065730535- Diabetes Treatment and Management
- Diabetes Management and Research
- Metabolism, Diabetes, and Cancer
- Pancreatic function and diabetes
- Diabetes and associated disorders
- Diabetes, Cardiovascular Risks, and Lipoproteins
- Hyperglycemia and glycemic control in critically ill and hospitalized patients
- Diet and metabolism studies
- Diabetes Management and Education
- Chronic Kidney Disease and Diabetes
- Lipoproteins and Cardiovascular Health
- Clinical practice guidelines implementation
- Liver Disease Diagnosis and Treatment
- Chronic Disease Management Strategies
- Pharmacology and Obesity Treatment
- Health Systems, Economic Evaluations, Quality of Life
- Gastric Cancer Management and Outcomes
- Medication Adherence and Compliance
- Thyroid Cancer Diagnosis and Treatment
- Chronic Lymphocytic Leukemia Research
- Gestational Diabetes Research and Management
- Primary Care and Health Outcomes
- Diet, Metabolism, and Disease
- Cardiovascular Function and Risk Factors
- Obesity and Health Practices
LMC Diabetes & Endocrinology (Canada)
2016-2025
Brampton Civic Hospital
2013-2024
CARE Canada
2022-2024
Scuola Superiore Sant'Anna
2024
Woodlands Hospital
2024
Mount Sinai Hospital
2016-2023
Concordia University
2023
University of Ottawa
2023
University of Calgary
2020-2023
Sunnybrook Health Science Centre
2023
OBJECTIVE To investigate the efficacy, safety, and tolerability of oral semaglutide added to insulin with or without metformin. RESEARCH DESIGN AND METHODS Patients type 2 diabetes uncontrolled on metformin were randomized 3 mg (N = 184), 7 182), 14 181) placebo 184) in a 52-week, double-blind trial. End points change from baseline week 26 HbA1c (primary) body weight (confirmatory secondary). Two estimands defined: treatment policy (effect regardless trial product discontinuation rescue...
It is thought that a reduction in the frequency of basal insulin injections might facilitate treatment acceptance and adherence among patients with type 2 diabetes. Insulin icodec analogue designed for once-weekly administration development diabetes.We conducted 26-week, randomized, double-blind, double-dummy, phase trial to investigate efficacy safety as compared once-daily glargine U100 who had not previously received long-term whose diabetes was inadequately controlled (glycated...
Inadequate dose titration and poor adherence to basal insulin can lead suboptimal glycemic control in persons with type 2 diabetes (T2D). Once-weekly icodec (icodec) is a analogue that development aimed at reducing treatment burden.
Canagliflozin reduced renal and cardiovascular events in people with type 2 diabetes the CREDENCE trial. We assessed efficacy safety of canagliflozin by initial estimated glomerular filtration rate (eGFR).CREDENCE randomly assigned 4401 participants an eGFR 30 to <90 ml/min per 1.73 m2 substantial albuminuria 100 mg or placebo. used Cox proportional hazards regression analyze effects on outcomes within screening subgroups (30 <45, 45 <60, 60 m2) linear mixed models slope.At screening, 1313...
Mortality rates from chronic kidney disease (CKD) have increased in the last decade. In this pre-specified analysis of DAPA-CKD trial, we determined effects dapagliflozin on cardiovascular and non-cardiovascular causes death.DAPA-CKD was an international, randomized, placebo-controlled trial with a median 2.4 years follow-up. Eligible participants were adult patients CKD, defined as urinary albumin-to-creatinine ratio (UACR) 200-5000 mg/g estimated glomerular filtration rate (eGFR) 25-75...
Insulin icodec (icodec) is a novel once-weekly basal insulin analog. This trial investigated two approaches for switching to versus once-daily glargine 100 units/mL (IGlar U100) in people with type 2 diabetes receiving daily and one or more oral glucose-lowering medications.This multicenter, open-label, treat-to-target phase randomized (1:1:1) eligible insulin-treated (total dose 10-50 units) (HbA1c 7.0-10.0% [53.0-85.8 mmol/mol]) an initial 100% loading (in which only the first was doubled...
This pre-specified analysis of DAPA-CKD assessed the impact sodium-glucose cotransporter 2 inhibition on abrupt declines in kidney function high-risk patients based having chronic disease (CKD) and substantial albuminuria. was a randomized, double-blind, placebo-controlled trial that had median follow-up 2.4 years. Adults with CKD (urinary albumin-to-creatinine ratio 200–5000 mg/g estimated glomerular filtration rate 25–75 mL/min/1.73m2) were randomized to dapagliflozin 10 mg/day matched...
To examine the efficacy and patient satisfaction of intermittently scanned continuous glucose monitoring (isCGM) in adults using non-insulin therapies for management type 2 diabetes.The IMMEDIATE study was a multisite, open label, randomized controlled trial with follow-up at 16 weeks. Adults diabetes least one therapy, an HbA1c 7.5% or higher (≥ 58 mmol/mol), were 1:1 to receive isCGM device plus self-management education (isCGM + DSME) DSME alone. Enrolment occurred from 8 September 2020...
OBJECTIVE The Dapagliflozin and Prevention of Adverse outcomes in Chronic Kidney Disease (DAPA-CKD) study demonstrated risk reduction for kidney cardiovascular with dapagliflozin versus placebo participants chronic disease (CKD) without diabetes. We compared according to baseline glycemic status. RESEARCH DESIGN AND METHODS enrolled CKD, estimated glomerular filtration rate (eGFR) 25–75 mL/min/1.73 m2, urinary albumin-to-creatinine ratio 200–5,000 mg/g. primary composite end point was...
To describe the phase 3a ONWARDS clinical development programme investigating insulin icodec (icodec), a once-weekly basal insulin, including design and rationale for each of 1-6 trials.Six randomized controlled trials have been initiated in adults with type 2 diabetes (T2D) (insulin-naive: 1, 3 5; previously insulin-treated: 4) 1 (T1D) (ONWARDS 6). Each trial will investigate use unique scenario, consideration long-term safety varied comparator treatments (insulin glargine U100 or U300...
Diabetes mellitus is a disease that takes heavy toll on the lives of people who have received diagnosis. For those diagnosed with T1D, it major life stress (and can become medical emergency) often dominates focus individuals and their families. T2D be (often for first several years) asymptomatic or cause symptoms are relatively easy to ignore. Yet, minor metabolic aberrations develop into larger ones eventually affect most physiological systems lead characteristic end-stage complications...
This post hoc analysis assessed continuous glucose monitoring (CGM)-based metrics and hypoglycemia duration with once-weekly insulin icodec versus once-daily basal analogs in insulin-experienced individuals long-standing type 2 diabetes from two 26-week phase 3a trials (ONWARDS ONWARDS 4).
Insulin efsitora alfa (efsitora) is a new basal insulin designed for once-weekly administration. Data on safety and efficacy have been limited to small, phase 1 or 2 trials.
Although nonalcoholic fatty liver disease (NAFLD) is frequent in obesity, the metabolic determinants of advanced remain unclear. Adipokines reflect inflammation and insulin resistance associated with obesity may identify NAFLD. At time surgery, 142 consecutive patients underwent biopsy had their preoperative demographic clinical data obtained. Liver histology was scored by NAFLD activity score, subdivided into four groups. Concentrations retinol-binding protein 4 (RBP4), adiponectin, tumor...
A head-to-head randomised trial was conducted to evaluate hypoglycaemia safety with insulin degludec 200 U/ml (degludec U200) and glargine 300 (glargine U300) in individuals type 2 diabetes treated basal insulin.This (1:1), open-label, treat-to-target, multinational included diabetes, aged ≥18 years HbA1c ≤80 mmol/mol (9.5%) BMI ≤45 kg/m2. Participants were previously or without oral glucose-lowering drugs (excluding secretagogues) had fulfil at least one predefined criterion for risk. Both...
<h3>Background:</h3> Nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH) account for a growing proportion of cases, there is need to better understand future burden. We used modelling framework forecast the burden NAFLD NASH Canada. <h3>Methods:</h3> Markov model fibrosis progression from stage F0 (no fibrosis) F4 (compensated cirrhosis) subsequent decompensated cirrhosis, hepatocellular carcinoma, transplantation liver-related death among Canadians with 2019...
KEY POINTS The goal of the Canadian Cardiovascular Harmonized National Guideline Endeavour (C-CHANGE) process is to give all health care providers easy access a comprehensive and practical set harmonized guideline recommendations. Clinicians claim that there are too many guidelines
There is a dearth of published literature comparing glucose variability (GV) between different insulin regimens in type 2 diabetes. This cohort study compares GV using continuous monitoring (CGM) patients with well-controlled diabetes four common regimens: basal + oral drugs (BO), glucagon-like peptide 1 receptor agonist (GLP-1 RA) (BGLP), premixed (PM), and basal-bolus (BB).Consecutive from three endocrinology clinics who met criteria-type diabetes, age 18 to 80 years, BMI ≤ 45 kg/m2,...